


SUPPLEMENTARY DATA

Supplementary Figure 1. SLIMM-T2D Study Patients Randomized to Roux-en-Y Gastric Bypass (RYGB) or Intensive Medical Diabetes and Weight Management (IMWM)



SUPPLEMENTARY DATA

Supplementary Table 1. Serious Adverse Events

	RYGB	IMWM
	n=20 events in 11 participants _a	n=7 events in 5 participants _b
Cardiac		
CV Death - resuscitated		1 ^c
MI		
Stroke		
Revascularization	1	
Hospitalization for Heart Failure		1
Supraventricular arrhythmia		2
Presyncope		2
Vascular	1 ^d	
Gastrointestinal Surgery		
Marginal Ulcer	2	
Lysis of Adhesions	3	
Cholestasis/Cholecystitis	3	
Paniclectomy	2	
Orthopedic	2	1
Renal	3 ^e	
Cancer	1 ^f	
Psychiatric	2	

Food and Drug Administration (FDA) criteria of serious adverse event include death, life-threatening, hospitalization (initial or prolonged), disability or permanent damage, required intervention to prevent permanent damage, congenital anomaly/birth defect, or other important medical event that may jeopardize the patient or require medical or surgical intervention to prevent one of the other outcomes [<http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm>, accessed November 18, 2016].

^a One participant had five events, one participant had three events, three participants had two events each, and the remainder had a single event.

^b One participant had three events and the remainder had a single event.

^c Successfully resuscitated out of hospital arrest.

^d Pulmonary Embolism.

^e Acute Kidney Injury (1); Nephrolithiasis (1); Urinary Tract Infection (1).

^f Breast cancer.